<DOC>
	<DOCNO>NCT00528619</DOCNO>
	<brief_summary>This study assess maximum tolerate dose , overall safety antitumor activity SU011248 combination pemetrexed , pemetrexed cisplatin pemetrexed carboplatin patient advance solid tumor .</brief_summary>
	<brief_title>A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed , Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients diagnosis solid cancer responsive standard therapy standard therapy exist . Patient good performance status ( ECOG 0 1 ) . Prior treatment either pemetrexed SU011248 . Coughing blood within 4 week start study treatment ( small amount okay ) . Hypertension control medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Solid tumor malignancy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Mesothelioma</keyword>
</DOC>